CareDx

CareDx reports Q3 2024 revenue of $82-83M, up 23% YoY, with Testing Services volume at 44,600, up 16% YoY. Testing services revenue is $60-61M, up 26% YoY. Patient and Digital Solutions revenue is $11.9M, up 20% YoY, and Products revenue is $10.2M, up 7% YoY. Cash, cash equivalents, and marketable securities total $240M with no debt. Financial results to be reported on November 4, 2024.

CareDx granted Jing Huang, the new Chief Data and AI Officer, 15,547 restricted stock units and an option to purchase 22,248 shares of common stock, as an inducement for employment, under the 2019 Inducement Equity Incentive Plan.

CareDx appoints Jing Huang Ph.D. as Chief Data and AI Officer to lead data science initiatives, leveraging AI for enhanced patient care and operational efficiency. Huang's role supports CareDx's long-term growth strategy, to be detailed at an Investor Day on October 15, 2024.

CareDx to host Investor Day on Oct 15, 2024, in NYC, featuring leadership team presentations. Register for in-person attendance or listen to the live webcast on investors.caredx.com.

CareDx announced that the DOJ concluded its investigation with no finding of wrongdoing and declined to take further action. This follows the SEC's decision in 2023 to close its investigation without action. The qui tam complaint, filed in 2021, is now unsealed, and CareDx will defend itself if the former employee proceeds with litigation.